SCHEMBL21592301

SCHEMBL21592301

COc1cc(CN(CCCn2cnc3ccccc32)Cc2c[nH]c3ccccc3c2=O)ccn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.35
▸ HTT P42858 3/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MKNK1 Q9BUB5 2/20 0.34
▸ MKNK2 Q9HBH9 2/20 0.34
▸ PRKD1 Q15139 2/20 0.34
▸ TDP1 Q9NUW8 2/20 0.34
▸ MAPT P10636 4/20 0.34
▸ LMNA P02545 4/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ HTR1A P08908 3/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ TSPO P30536 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591563 0.86 SMN1; SMN2 (0.37) SMN1; SMN2HTTMEN1KMT2ATDP1
SCHEMBL21591545 0.81 SMN1; SMN2 (0.33) SMN1; SMN2HTTMEN1KMT2ATDP1
SCHEMBL21591458 0.78 PKM (0.37) SMN1; SMN2HTTMEN1KMT2ATDP1
SCHEMBL21592290 0.76 CYP1A2 (0.39) MEN1KMT2ALMNAALDH1A1TSHR
SCHEMBL21592269 0.76 SMN1; SMN2 (0.36) SMN1; SMN2HTTMEN1KMT2AMAPT
SCHEMBL21591438 0.76 SMN1; SMN2 (0.36) SMN1; SMN2HTTMEN1KMT2ATDP1
SCHEMBL21591542 0.75 LTA4H (0.35) MEN1KMT2ALMNAALDH1A1TSHR
SCHEMBL21592260 0.72 LOX (0.38) KDM4ETP53PRKCBPIM1GSK3B
SCHEMBL21592259 0.72 IDH1 (0.41) ALDH1A1TSHRMAPK1GSK3B
SCHEMBL21592246 0.68 SMN1; SMN2 (0.46) SMN1; SMN2HTTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS SMN1; SMN2 3753/4885HTT 4397/4885MEN1 2184/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS SMN1; SMN2 3753/4885HTT 4397/4885MEN1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback